EU to study potential vaccine for Lyme disease

The European Union has decided to investigate the potential for a vaccine against Lyme disease, the world's most prevalent tick-borne illness, according to developers Pfizer and Valneva. The joint venture announced earlier this year that their experimental vaccine, PF-07307405, demonstrated a 70% efficacy rate for individuals aged five and older in combating a condition that presently lacks a licensed vaccine.

Despite a setback earlier in the year, the European Medicines Agency (EMA) has approved the firms' application for approval of the treatment.

Lyme disease, which often presents as rashes, flu-like symptoms, and, in rare instances, neurological issues, poses a significant health concern for those affected by tick bites. In certain cases, the disease can lead to neurological complications. A study conducted in 2022 estimated that over 14% of the global population has contracted the disease, highlighting the need for improved prevention measures. Climate change, which is causing longer, drier summers, could potentially exacerbate transmission rates.

Exposure to Lyme disease is not limited to a small subset of the population; an estimated 200 million people reside in areas of Europe where the risk of infection is high. Pfizer's Chief Vaccine Officer, Annaliesa Anderson, expressed optimism about the development of vaccination as a crucial new defense against this debilitating illness.

Valneva's Chief Executive, Thomas Lingelbach, agreed that the EMA's acceptance of their application marks a significant milestone, particularly considering the large number of people living in Lyme disease-prone regions across Europe.